The research, led by Andrew C. Dudley, PhD, has implications for developing cancer drugs that target blood vessels that feed tumors.
In cell lines, scientists at the joint UNC-NC State biomedical engineering program have shown that the new nano particles can stealthily enter cancer cells and release a known drug to attack tumors from the inside.
Brian Strahl, PhD, and his band of biochemists unravel the complicated mysteries of the epigenetic code to find a culprit in cancer development.
Led by Bryan L. Roth, MD, PhD, three UNC labs will develop the next generation neuroscience tool-kit to accelerate novel treatments for neuropsychiatric and a host of other diseases.
Jordan Sanderson, a 25-year-old Carteret County native and current Nash County resident, shares how her father’s diagnosis and treatment challenged her and aged her in a good way.
With his selection to the NIH Council of Councils, Terry Magnuson, PhD, becomes the first UNC scientist appointed to the board dedicated to funding the biggest ideas in medical research.
Sixteen years after scientists found the genes that control the circadian clock in all cells, the lab of UNC’s Aziz Sancar, MD, PhD, discovered the mechanisms responsible for keeping the clock in sync.
Upstream of the proteins that cancer cells use to proliferate sits RBM4, a gene-splicing protein that UNC researcher Zefeng Wang, PhD, discovered is drastically reduced in human lung and breast cancer cells.
Research led by UNC’s Kathleen Caron, PhD, shows that halting the protein CXCR7 leads to over activation of adrenomedullin, a hormone needed at proper levels for normal cardiovascular development
Eight breast cancer genes identified using new approach
For more than 20 years, Sharon Campbell, PhD, has been studying Ras, a protein implicated in 30 percent of all cancers. Now she’s on the hunt for alternative ways to shut the protein down.
The work, led by researchers at the UNC Lineberger Comprehensive Cancer Center, UNC-Chapel Hill and other TCGA sites, revamps traditional ideas of how cancers are diagnosed and treated and could also have a profound impact on the future landscape of drug development.
Henrik Dohlman, PhD, discovered why seemingly identical cells might react differently to the chemical signals inside our bodies and the drugs we use to battle diseases.
Andrew Dudley, PhD, assistant professor of cell biology and physiology, was recently named an American Cancer Society Research Scholar. His funded research proposal will investigate “Mechanisms of tumor escape from anti-angiogenic therapy.”
Greg Wang, PhD, assistant professor of biochemistry and biophysics, received a grant to study "Novel Approaches to Target PRC2 Enzymatic Complexes for the Treatment of Hematopoietic Malignancies."
Though cancer screening has come a long way, physicians still do not thoroughly discuss with patients the advantages and disadvantages of these procedures before decisions are made to undergo the screenings, according to a new study co-authored by a UNC physician.
Health-e-NC, a core project of the Lineberger Comprehensive Cancer Center, supported by the University Cancer Research Fund, announces its fourth round of pilot funding to stimulate innovative intervention research to optimize cancer outcomes.
The discovery, from the lab of Brian Strahl, PhD, offers insights for the creation of better, more targeted therapies for various forms of cancer.
Why are some 75-year-olds downright spry while others can barely get around? New research provides part of the explanation.
By waiting to trigger the drug's potency, the method may provide a better route toward treating malignant tumors.